BPC-157 and Other Peptides: Miracle Molecules or Hype?

About this episode

Dr. Adil Ahmed and Dr. Humayun Naqvi break down the peptide craze, starting with what a peptide actually is, then weighing the hype against the evidence for BPC-157 (the 'Wolverine shot'), the angiogenesis-driven healing seen in rat studies, and its theoretical tumor-growth risk. They cover GLP-1s and insulin as proven peptides, sermorelin, epitalon and telomerase, melanotan, and thymosin alpha-1's real clinical-trial data in hepatitis, HIV and sepsis, while warning about unregulated gray-market injections and the financial conflicts of cash-pay peptide clinics.

What we cover in this episode

1. What is a peptide and how do peptides signal in the body
2. BPC-157 safety, benefits and tumor growth risk
3. Does BPC-157 actually heal tendons and injuries
4. GLP-1s and insulin as proven peptide therapies
5. Sermorelin for muscle growth and its melanoma risk
6. Epitalon, telomerase and the longevity vs cancer tradeoff
7. Thymosin alpha-1 clinical evidence in HIV, hepatitis and sepsis
8. Why peptides like BPC-157 lack human studies and FDA approval
9. Conflicts of interest at cash-pay peptide and wellness clinics

Your hosts

Dr. Humayun NaqviPreventive Cardiologist · West Houston Heart Center

Dr. Adil AhmedOrthopedic Surgeon · Baylor College of Medicine

More episodes